Results 91 to 100 of about 6,869 (208)

A Comparative Study of the Effects of Intravitreal Anidulafungin, Voriconazole, and Amphotericin B in an Experimental Candida Endophthalmitis Model

open access: yes, 2017
Purpose: To compare the safety and efficacy of intravitreal anidulafungin injection with voriconazole and amphotericin B (Amp B) in an experimental Candida endophthalmitis (CE) model.Methods: Intravitreal 1 x 10(5) CFU/0.1 ml Candida albicans was ...
Uyanık, Muhammet Hamidullah   +7 more
core   +1 more source

Cost-effectiveness of three echinocandins and fluconazole in the treatment of candidemia and/or invasive candidiasis in nonneutropenic adult patients

open access: yesClinicoEconomics and Outcomes Research, 2015
S Grau,1 JC Pozo,2 E Romá,2 M Salavert,3 JA Barrueta,4 C Peral,4 I Rodriguez,5 D Rubio-Rodríguez,6 C Rubio-Terrés6 1Hospital del Mar (IMIM), Barcelona, 2Hospital Universitario Reina Sofía, Córdoba, 3Hospital ...
Grau S   +8 more
doaj  

Safety and efficacy of echinocandin antifungal agents in Candida albicans endophthalmitis

open access: yesAntimicrobial Agents and Chemotherapy
To evaluate the safety and efficacy of echinocandins (rezafungin, RZF; anidulafungin, AFG) in Candida albicans (C. albicans) endophthalmitis, with a particular focus on the novel drug RZF.
Yue Zhang, Yi Tang, Yanjie Zhou, Hong Wu
doaj   +1 more source

[Anidulafungin].

open access: yesRevista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2008
Anidulafungin is a new echinocandin antifungal agent recently approved in Spain by the Spanish Drug Agency. As other echinocandins, it inhibits a selective target, 1,3- beta-D-glucan synthesis, a major structural component of the fungal cell wall which is not present in mammalian cells, this avoiding toxicity problems.
M, Gobernado, E, Cantón
openaire   +1 more source

Anidulafungin for Neonatal Hematogenous Candida Meningoencephalitis: Identification of Candidate Regimens for Humans Using a Translational Pharmacological Approach

open access: yes, 2012
Hematogenous Candida meningoencephalitis (HCME) is a serious infection in premature neonates. Anidulafungin is an echinocandin antifungal agent with potent activity against Candida spp., but its efficacy ...
Peter A. Warn   +22 more
core   +1 more source

Anidulafungin liposome nanoparticles exhibit antifungal activity against planktonic and biofilm Candida albicans

open access: yes, 2020
Fungal infections can cause significant patient morbidity and mortality. Nanoparticle therapeutics have the potential to improve treatment of these infections.
Luc Langlois   +13 more
core   +1 more source

Anidulafungin increases the antibacterial activity of tigecycline in polymicrobial Candida albicans/Staphylococcus aureus biofilms on intraperitoneally implanted foreign bodies

open access: yes, 2018
Objectives: We aimed to establish a novel murine intra-abdominal foreign body infection model to study the activity of anidulafungin and tigecycline against dual species Candida albicans/Staphylococcus aureus biofilms.
Rogiers, Ona   +15 more
core   +1 more source

Multicenter Analysis of Anidulafungin Use in Invasive Candida Infections

open access: yes, 2019
Giriş: Tüm dünyada fungal infeksiyonlar önemli bir sorun olup değişen hasta profili ile birlikte sıklığı artmıştır. Özellikle kandida halen en sık karşılaşılan fungal etken olup son yıllarda albikans dışı kandidaların önemi artmıştır.
Kutsoylu, Oya Eren   +6 more
core   +1 more source

Anidulafungin in the treatment of patients with invasive candidiasis

open access: yes, 2008
Echinocandins have emerged as important agents for the treatment of invasive candidiasis. Forthcoming guidelines are expected to recommend an echinocandin agent as initial primary therapy in patients who are severely ill and/or have risk factors for ...
Cubillos, G Fernando, Kett, Daniel H
core   +1 more source

Discovery of Small-Molecule PD-L1 Inhibitors via Virtual Screening and Their Immune-Mediated Anti-Tumor Effects

open access: yesPharmaceuticals
Background/Objectives: Monoclonal antibodies targeting the PD-1/PD-L1 immune checkpoint have achieved clinical success but face drawbacks such as poor oral bioavailability, limited tumor penetration, and immune-related adverse events.
Chunlai Feng   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy